Big BusinessVaccines have been a big business for the firms that make them, with Pfizer, BioNTech’s partner outside of China, raising its forecast for 2021 vaccine sales to $26 billion just this week.
Shares of many of the U.S.-listed companies had fallen late in Wednesday’s regular trading session after Tai’s comments.Read more: Analysts say investor fears of U.S.
vaccine waiver support are overblownThe U.S. move “probably isn’t great news for the vaccine manufacturers who will now face generic copies of their vaccine, but as the mutation of the virus has shown, continued research and innovation will be needed and that should provide those companies with future earnings from newer vaccines so I would expect the impact to be short-lived and.